/
FDMT
$12.88+$1.28 (+11.03%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$606.4M
52M shares
52-week range
$3.68 – $13.33
95% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-11.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M | $7.0M | $13.6M | $18.0M | $3.1M | $20.7M | $37.0K | $85.2M |
| Cost of revenue | $18.4M | $38.7M | $53.0M | $61.4M | $80.3M | $97.1M | $141.3M | $7.6M |
| Gross profit | −$4.2M | −$31.7M | −$39.4M | −$43.3M | −$77.1M | −$76.4M | −$141.3M | $77.6M |
| Gross margin | -30.0% | -454.2% | -289.6% | -240.2% | -2464.8% | -368.5% | -381789.2% | 91.1% |
| R&D | $18.4M | $43.9M | $53.0M | $61.4M | $80.3M | $97.1M | $141.3M | $195.7M |
| Operating income | −$10.4M | −$50.8M | −$56.7M | −$71.3M | −$110.0M | −$112.9M | −$187.8M | −$159.5M |
| EBITDA | −$9.7M | −$44.6M | −$55.2M | −$69.8M | −$105.1M | −$96.6M | −$154.2M | −$132.5M |
| Net income | −$9.6M | −$49.3M | −$56.7M | −$71.3M | −$107.5M | −$100.8M | −$160.9M | −$140.1M |
| Net margin | -67.6% | -705.8% | -416.5% | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| EPS (diluted) | -0.76 | -2.00 | -2.12 | -2.46 | -3.12 | -2.58 | -2.98 | -2.42 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12M | $-4.03 | $-4.10–$-3.97 | 5 |
| 2027 | $17M | $-4.03 | $-4.16–$-3.79 | 5 |
| 2028 | $44M | $-3.93 | $-5.41–$-2.80 | 4 |
| 2029 | $127M | $-3.53 | $-8.33–$-1.28 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
4D Molecular Therapeutics, Inc. Common Stock
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
www.4dmoleculartherapeutics.com- Employees
- 196
- IPO / List date
- Dec 11, 2020
- HQ
- EMERYVILLE, CA
Held by traders on TradeandTell
No one on the platform currently holds FDMT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 578,265 | $5.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FDMT yet.
